Osimertinib versus first/second generation tyrosine kinase inhibitors as first-line therapy for metastatic EGFR-mutated non-small cell lung carcinoma: Overall survival using real-world data from TriNetX platform

被引：0
|
作者：
Ugidos De La Varga, L. [1 ]
Hernandez-Ibarburu, G. [2 ]
Jimenez, A. Parralejo [3 ]
Rodriguez-Castano, J. D. [1 ]
Serrano, J. J. [1 ]
Ayuso, A. [4 ]
Rodriguez Pascual, J. [1 ]
机构：
[1] Inst Oncol Vithas, Med Oncol, Madrid, Spain
[2] TriNetX, Acad Res, Sint Martens Latem, Belgium
[3] TriNetX, Clin Res Partnerships, Sint Martens Latem, Belgium
[4] Fdn Vithas, Direcc Cient, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1331
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1274P
引用
收藏
页码：S814 / S814
页数：1
相关论文
共 50 条
  • [1] Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting
    Apple, Jon
    Shenolikar, Rahul
    De Silva, Kevin
    Sun, Ping
    Spira, Alexander
    CANCER MEDICINE, 2023, 12 (12): : 13415 - 13425
  • [2] Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: A Chinese, multicenter, real-world cohort study
    Zhang, D.
    Liu, X.
    Shen, F.
    Zhao, D.
    Shi, Y.
    Zhang, H.
    Liu, J.
    Gao, X.
    Chen, M.
    Zhao, J.
    Zhong, W.
    Xu, Y.
    Wang, M.
    ANNALS OF ONCOLOGY, 2023, 34
  • [3] First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
    Jeong, Byeong-Ho
    Um, Sang-Won
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
  • [4] Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01
    Hibino, Makoto
    Imamura, Yoshinori
    Shimoyama, Rai
    Fukui, Tomoya
    Fukai, Ryuta
    Iwase, Akihiko
    Tamura, Yukihiro
    Chihara, Yusuke
    Okabe, Takafumi
    Uryu, Kiyoaki
    Okuda, Tadahisa
    Taguri, Masataka
    Minami, Hironobu
    TARGETED ONCOLOGY, 2024, 19 (06) : 925 - 939
  • [5] Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study
    Zhang, Dongming
    Liu, Xiaoyan
    Shen, Fangfang
    Zhao, Dahai
    Shi, Yuequan
    Zhang, Haoran
    Liu, Jia
    Gao, Xiaoxing
    Chen, Minjiang
    Zhao, Jing
    Zhong, Wei
    Gao, Junzhen
    He, Min
    Liu, Yonggang
    Yang, Xiaoling
    Qin, Jianwen
    Tang, Yuling
    Mu, Xinlin
    Gu, Yangchun
    Zhang, Shucai
    Chen, Xueqin
    Pang, Li
    Meng, Qingwei
    Guo, Ye
    Zhang, Yuhui
    Li, Wei
    Xing, Puyuan
    Cheng, Yuan
    Xin, Tao
    Li, Qingxia
    Li, Yu
    Chen, Jun
    Gao, Feng
    Jin, Bo
    Rossi, Antonio
    Adachi, Hiroyuki
    Guerrera, Francesco
    Husain, Hatim
    Xu, Yan
    Wang, Mengzhao
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (11) : 2229 - +
  • [6] Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib
    Nieva, J.
    Taylor, A.
    Servidio, L.
    Sun, P.
    Okhuoya, P.
    Horvat, P.
    Tolani, E.
    Magee, K.
    Mathur, R.
    Balakrishna, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1113 - S1113
  • [7] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
    Popat, Sanjay
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 192 - 193
  • [8] Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis
    Feng-Che Kuan
    Liang-Tseng Kuo
    Min-Chi Chen
    Cheng-Ta Yang
    Chung-Sheng Shi
    David Teng
    Kuan-Der Lee
    British Journal of Cancer, 2015, 113 : 1519 - 1528
  • [9] Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis
    Kuan, Feng-Che
    Kuo, Liang-Tseng
    Chen, Min-Chi
    Yang, Cheng-Ta
    Shi, Chung-Sheng
    Teng, David
    Lee, Kuan-Der
    BRITISH JOURNAL OF CANCER, 2015, 113 (10) : 1519 - 1528
  • [10] THE REAL-WORLD EFFICACY OF FIRST-LINE TYROSINE KINASE INHIBITORS IN ASIAN PATIENTS WITH EGFR MUTATION NON-SMALL CELL LUNG CANCER
    Su, Vincent Yi-Fong
    Yang, Kuang-Yao
    Chen, Yuh-Min
    RESPIROLOGY, 2018, 23 : 21 - 22
12345